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Abstract: Lithiation of N'-(2-methylbenzyl)-N,N-dimethylurea 
and N-(2-methylbenzyl)pivalamide with two mole equivalents of 
t-BuLi at -78 °C takes place on the nitrogen and on the methyl 
group at position 2. The lithium reagents thus obtained react with 
a variety of electrophiles to give the corresponding side-chain 
substituted derivatives in high yields. Dehydration of the products 
obtained from reactions with carbonyl compounds in some cases 
gives the corresponding tetrahydroisoquinolines in excellent 
yields, while in other cases dehydration takes place within the 
substituted side chain to produce the corresponding alkenes in 
excellent yields. 
Key words: lateral lithiation, isoquinolines, N'-(2-methylbenzyl)-
N,N-dimethylurea, N-(2-methylbenzyl)pivalamide, synthesis, 
dehydration 
Lithiation of benzylic alkyl groups that are ortho- to a 
directing metallating group is an important methodology 
in organic synthesis.1-3 Such lateral lithiation of benzeno-
id aromatics requires a stabilising group capable of either 
delocalising negative charge or stabilising an organoli-
thium by coordination.1 Nitrogen-based stabilising 
groups placed on the ortho-position have been used for a 
number of lateral lithiations of simple aromatics and 
heterocycles.4-8  
Tetrahydroisoquinolines are important compounds, many 
of which have useful biological properties,9-16 and there 
is therefore considerable interest in their syntheses. For 
example, recent syntheses of tetrahydroisoquinolines 
have included the use of reactions such as Pictet-
Spengler,17 Bischler-Napieralski,18 intramolecular 
Horner,19 Friedel-Crafts20 and others.21 Another poten-
tially useful approach to the synthesis of 
1,2,3,4-tetrahydroisoquinolines involves lithiation of N-
(tert-butoxycarbonyl)-2-methylbenzylamine (1) with 
sec-BuLi at -60 °C to give the corresponding lithium 
intermediate, which on reaction with veratraldehyde 
produces 2 in 66% yield (Scheme 1). Treatment of 2 
with trifluoroacetic acid (TFA) gives the corresponding 
tetrahydroisoquinoline 3 in 87% yield.22 
However, the cyclization appears to require the presence 
of the 4-methoxy group in the electrophile, presumably 
through stabilization of the intermediate carbenium ion 
in the cyclization step. The corresponding unsubstituted 
phenyl compound (when benzaldehyde was used as the 
electrophile) failed to cyclise under similar, or even more 
strongly acidic, conditions. Also, no cyclization took 
place when other carbonyl compounds, e.g. benzophe-
none and cyclohexanone, were used.22 
We were interested to see whether this latter approach 
could be made more general as a synthesis of tetrahy-
droisoquinoline derivatives by using a different substitu-
ent on nitrogen. Based on our previous experience,7,8,23 
we decided to attempt lateral lithiation of pivaloyl- and 
dimethylaminocarbonyl-substituted 2-methylbenzyl-
amine, followed by reaction with appropriate electro-
philes and subsequent cyclization. The dimethylamino 
and tert-butyl groups in these compounds might be ex-
pected to render the NH group, respectively, more and 
less nucleophilic in the cyclization step. We now report 
the successful lateral lithiation and substitution of 
N'-(2-methylbenzyl)-N,N-dimethylurea and N-(2-methyl-
benzyl)pivalamide using t-Buli at -78 °C. In most of the 
cases tried, the urea derivatives indeed cyclised success-
fully to tetrahydroisoquinoline derivatives, whereas the 
pivaloyl derivatives mostly yielded 2-alkenylbenzyl-
amine derivatives. 
N'-(2-Methylbenzyl)-N,N-dimethylurea (5) and 
N-(2-methylbenzyl)pivalamide (6) were synthesised in 
high yields from reactions of 2-methylbenzylamine (4) 
with pivaloyl chloride and dimethylcarbamoyl chloride, 
respectively, in dichloromethane (DCM) in the presence 
of triethylamine (TEA) as a base (Scheme 2). 
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Scheme 1 Synthesis of substituted tetrahydroisoquinoline 3
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Scheme 2 Synthesis of N-substituted 2-methylbenzylamines 5 and 6 
Lateral lithiation of N'-(2-methylbenzyl)-N,N-
dimethylurea (5) was carried out with t-BuLi (2.2 mole 
equivalents) at –78 °C in THF. Addition of the first mole 
of t-BuLi provided the monolithium reagent 7 as a yel-
low solution and the second mole produced a dilithium 
reagent (presumed to be 8) as a reddish brown solution 
(Scheme 3). The dilithium reagent was allowed to react 
with a range of electrophiles under identical conditions. 
Following work-up the crude products were purified by 
column chromatography to give the corresponding subs-
tituted derivatives 9-14 (Scheme 3) in high yields (Table 
1). 
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Scheme 3 Synthesis of 9-14 via lithiation and substitution of 5 
Table 1 Synthesis of N'-(2-(substituted methyl)benzyl)-N,N-
dimethylureas 9-14 according to Scheme 3 
Product Electrophile E Yield (%)a 
9 PhCHO PhCH(OH) 77 
10 4-MeOC6H4CHO 4-MeOC6H4CH(OH) 79 
11 PhCOMe PhCH(OH)Me 74 
12 Ph2CO Ph2C(OH) 76 
13 EtI Et 82 
14 D2O D 83 
a Yield of isolated product after purification by column chromatogra-
phy. 
As can be seen from Table 1, the process is successful 
with a variety of different electrophiles. The 1H NMR 
spectra of compounds 9-11 showed that the signals of the 
two protons of each of the two CH2 groups appeared 
separately, verifying that they are diastereotopic.  
Lateral lithiation of N-(2-methylbenzyl)pivalamide (6) 
under similar conditions followed by reactions with a 
range of electrophiles also gave the corresponding subs-
tituted derivatives 15-22 (Scheme 4) in good yields (Ta-
ble 2). 
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Scheme 4 Synthesis of 15-22 via lithiation and substitution of 6 
The yields of pure products were high in all cases and 
the process was general to produce various side-chain 
substituted derivatives. The 1H NMR spectra of com-
pounds 15-17 also showed diastereotopicity for the two 
hydrogens of each of the two CH2 groups. The structure 
of one product (15) was confirmed by X-ray crystallo-
graphy (Figure 1).  
Table 2 Synthesis of N-(2-(substituted methyl)benzyl)pivalamides 
15-22 according to Scheme 4 
Product Electrophile E Yield (%)a 
15 PhCHO PhCH(OH) 84 
16 4-MeOC6H4CHO 4-MeOC6H4CH(OH) 89 
17 PhCOMe PhC(OH)Me 80 
18 Ph2CO Ph2C(OH) 88 
19 (CH2)5C=O (CH2)5C(OH) 76 
20 MeI Me 87 
21 EtI Et 88 
22 D2O D 85 
a Yield of isolated product after purification by column chromatogra-
phy. 
15 24  
Figure 1 X-ray crystal structures of compounds 15 and 24 
The next step was to investigate cyclization to the corre-
sponding tetrahydroisoquinolines of appropriate com-
pounds produced from lithiations of both 5 and 6. In-
deed, dehydration of compounds 9-11 took place 
smoothly and rapidly on treatment with trifluoroacetic 
anhydride (TFAA) at room temperature in DCM for 5 
minutes to produce the corresponding substituted tetra-
hydroisoquinolines 23-25, respectively, in excellent 
yields (Scheme 5). 
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Scheme 5 Synthesis of substituted tetrahydroisoquinolines 23-25 via 
dehydration 
The 1H NMR spectra of compounds 23-25 showed the 
expected diastereotopicity for the two pairs of hydrogens 
at positions 1 and 4 of the isoquinoline rings and the 
structure of compound 24 was confirmed by X-ray crys-
tallography (Figure 1).  
However, reaction of 12 with TFAA proceeded in a dif-
ferent manner to produce 26 in 95% yield (Scheme 6). 
The structure of 26 was confirmed by X-ray crystallo-
graphy (Figure 2). 
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Scheme 6 Synthesis of 26 via dehydration of 12 
In this case the intermediate formed is a doubly benzylic 
cation that is perhaps both more stable and more hin-
dered than those produced from 9-11. It appears that loss 
of a proton from the α-position is easier than cyclization, 
leading to the corresponding alkene 26. Even leaving the 
reaction mixture for longer with TFAA (and TFA pro-
duced in situ), in the hope that the alkene would proto-
nated and cyclize, failed to produce the tetrahydroiso-
quinoline. However, in the majority of cases tried, cycli-
zation to give tetrahydroisoquinolines was successful, 
indicating that the use of the dimethylaminocarbonyl-
substituted 2-methylbenzylamine is preferable to use of 
the previously reported Boc-protected substrate. 
26 28  
Figure 2 X-ray crystal structures of compounds 26 and 28 
By contrast, reactions of the corresponding pivaloyl 
derivatives did not lead to tetrahydroisoquinolines. For 
example, reaction of 15 with TFAA at room temperature 
in DCM for 5 minutes gave N-(2-(2-phenyl-2-
trifluoroacetoxyethyl)benzyl)pivalamide (27) in 97% 
yield (Scheme 7). 
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Scheme 7 Synthesis of 26 via dehydration of 15 
Treatment of 16 and 17 with TFAA under similar condi-
tions gave the corresponding unsaturated derivatives 28 
and 29, respectively (Scheme 8). Compounds 28 and 29 
were produced in 97 and 14% yield, respectively, when 
the reaction time was 5 minutes. The yield of 29 was 
improved to 72% when the reaction time was 1 h. Nei-
ther 28 nor 29 cyclized to their corresponding tetrahy-
droisoquinolines even when the mixtures were left to stir 
for 8 h. 
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Scheme 9 Synthesis of 31 and 32 via dehydration of 19 and 20, re-
spectively 
According to their 1H NMR spectra, both 28 and 29 were 
single geometrical isomers. The structure of 28 was 
shown by X-ray crystallography (Figure 2) to be the 
E-isomer. A Nuclear Overhauser Effect (NOE) experi-
ment for 29 clearly showed that when the C=CMe proton 
signal (δ = 2.05 ppm) was irradiated the signal corre-
sponding to H-3 (δ = 7.46 ppm) was enhanced, showing 
that compound 29 was also the E-isomer. 
The results of the attempted dehydration reactions can be 
rationalized by the processes outlined in Scheme 9, ac-
cording to which the first step would be to form a 
trifluoroacetate ester 31 from the alcohol 30. In a situa-
tion where the driving force for ionization is low (e.g. R1 
= Ph, R2 = H or R1 = H, R2 = alkyl) and the NHCOR 
group is relatively non-nucleophilic (e.g. R = tBu), under 
the mild reaction conditions used the reaction may stop 
at compound 31, allowing the isolation of compound 27 
(i.e. 31 with R1 = Ph, R2 = H, R = tBu), for example. 
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However, when the cation 32 is more stable (e.g. R1 = 
Ph, R2 = Ph, Me or R1 = 4-MeOC6H4, R2 = H), 31 does 
not survive the reaction conditions. The cation 32 can 
lose a proton either to form an alkene 33 or cyclise to 
form a tetrahydroisoquinoline 34. Alkene formation is 
favoured when the NHCOR group is not very nucleo-
philic (e.g R = tBu) or when cyclization is sterically 
hindered (e.g. R1 = R2 = Ph, even when R = NMe2). 
Cyclization is favoured when the NHCOR group is rela-
tively more nucleophilic (e.g. R = NMe2). In principle, 
reprotonation of 33 to give back cation 32 would be 
expected to be easier than reprotonation of 34. There-
fore, it might be possible to convert 33 into 34 in acid 
conditions. However, under the mild conditions used 
here the alkenes 33 appeared to be stable and no cycliza-
tions were observed. Therefore, if the ultimate goal is a 
cyclised product, it is important to use a sufficiently 
nucleophilic NHCOR group such as NHCONMe2, for 
which the cyclised product 34 is the normal product 
when the cationic centre is not too hindered. 
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Scheme 9 Possible processes involved during hydration experiments 
A simple, efficient and general procedure that allows 
lateral lithiation and substitution of 
2-methylbenzylamine derivatives has been demonstrated 
to provide various side-chain (methyl) substituted de-
rivatives in high yields. Dehydration of the products 
from reactions of the urea derivatives with aldehydes and 
ketones using trifluoroacetic anhydride generally gives 
the corresponding tetrahydroisoquinolines in excellent 
yields. However, when a bulky group, such as hydroxy-
diphenylethyl, is present at position 2, cyclization is not 
successful and dehydration takes place instead to pro-
duce a 2-alkenylbenzylamino derivative in high yield. 
N-2-(2-Hydroxy-2-arylalkyl)benzyl)pivalamides are not 
cyclised under such conditions. Instead, esterification of 
the hydroxyl group with TFAA or dehydration to give 
the corresponding alkenes takes place to give high yields 
of the corresponding products. The results have been 
rationalised in terms of a common set of reaction inter-
mediates. 
General Methods: Melting point determinations were performed 
by the open capillary method using a Gallenkamp melting point 
apparatus and are reported uncorrected. 1H and 13C NMR spectra 
were recorded on a Bruker AV400 spectrometer operating at 400 
MHz for 1H and 100 MHz for 13C measurements. Chemical shifts 
δ are reported in parts per million (ppm) relative to TMS and 
coupling constants J are in Hz and have been rounded to the near-
est whole number. 13C multiplicities were revealed by DEPT 
signals. Assignments of signals are based on integration values, 
coupling patterns and expected chemical shift values and have not 
been rigorously confirmed. Signals with similar characteristics 
might be interchanged. Low-resolution mass spectra were record-
ed on a Quattro II spectrometer, electron impact (EI) at 70 eV and 
chemical ionization (CI) at 50 eV by the use of NH3 as ionization 
gas. Accurate mass data were obtained on a MAT900 instrument. 
Electrospray (ES) analyses were performed on a ZQ4000 spec-
trometer in positive and negative ionisation modes. IR spectra 
were recorded on a Perkin Elmer Spectrum One FT-IR spectrome-
ter. Microanalyses were performed by Warwick analytical service 
at the University of Warwick. The X-ray single-crystal diffraction 
data were collected on a Nonius Kappa CCD diffractometer using 
graphite-monochromated Mo-Kα, (λ = 0.710 73 Å) radiation. 
Crystal and structure refinement data are shown the supporting 
information. The structures were solved by direct methods using 
SHELXS-9624 and refined with all data on F2 full-matrix least 
squares using SHELXL-97.25 Non-hydrogen atoms were generally 
refined anisotropically. Hydrogen atom positions were located 
from difference Fourier maps and a riding model with atomic 
displacement parameters 1.2 times (1.5 times for methyl groups) 
those of the atom to which they are bonded was used for subse-
quent refinements. Full crystallographic data have been deposited 
with the CCDC, reference numbers 737412, 737414, 737416 and 
737417, and can be obtained free of charge via 
http://www.ccdc.ac.uk/data_request/cif. Column chromatography 
was carried out using Fischer Scientific silica 60A (35-70 micron). 
Alkyllithiums were obtained from Aldrich Chemical Company 
and were estimated prior to use by the method of Watson and 
Eastham.26 Other chemicals were obtained from Aldrich Chemical 
Company and used without further purification. THF was distilled 
from sodium benzophenone ketyl. Other solvents were purified by 
standard procedures.27 
 
N'-(2-Methylbenzyl)-N,N-dimethylurea (5) 
A stirred mixture of 2-methylbenzylamine (4; 4.84 g; 40.0 mmol), 
dimethylcarbamoyl chloride (4.83 g, 45 mmol) and triethylamine 
(8 mL) in DCM (60 mL) was heated under reflux for 1 h. The 
mixture was poured onto H2O (50 mL) and the organic layer was 
separated, washed with H2O (2 x 25 mL), and dried (MgSO4) and 
the solvent was then removed under reduced pressure. The solid 
obtained was purified by crystallization from EtOAc/Et2O (1/3) to 
give pure 5 as a white crystalline solid.  
6.45 g (33.6 mmol, 84%); Mp: 82–83 °C. 
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1H NMR (400 MHz, CDCl3): δ = 7.19–7.01 (m, 4 H, Ar), 4.48 (br, 
exch., 1 H, NH), 4.31 (br, 2 H, CH2), 2.82 [s, 6 H, N(CH3)2], 2.26 
(s, 3 H, CH3). 
13C NMR (100 MHz, CDCl3): δ = 158.7 (C=O), 137.5 (C-1), 
136.8 (C-2), 130.8 (C-3), 128.8 (C-6), 127.9 (C-4), 126.5 (C-5), 
43.6 (CH2), 36.7 [N(CH3)2], 19.45 (CH3). 
MS (EI): m/z (%) = 192 (35) [M]+, 177 (5), 148 (7), 120 (49), 105 
(88), 104 (94) 91 (40), 77 (40), 72 (100), 65 (17), 46 (16), 44 (46), 
42 (16). 
MS (CI): m/z (%) = 210 (4) [M + NH4]+, 193 (100) [MH]+, 122 
(14), 120 (20), 103 (15), 89 (12), 52 (27), 46 (39), 44 (16). 
HRMS-CI: m/z [MH]+ calcd for C11H17N2O: 193.1335; found: 
193.1335. 
IR (FT): = 3317, 2925, 1635, 1533, 1353, 1231 cm-1. 
 
N-(2-Methylbenzyl)pivalamide (6) 
To a cooled solution (0 °C) of 4 (4.84 g, 40.0 mmol) and triethy-
lamine (6 mL) in DCM (100 mL) pivaloyl chloride (5.3 g, 44.3 
mmol) was slowly added in a drop-wise manner over 30 min. The 
reaction mixture was stirred at 0 °C for an extra 1 h. The mixture 
was poured onto H2O (100 mL) and the organic layer was sepa-
rated, washed with H2O (2 x 50 mL), and dried (MgSO4) and the 
solvent was then removed under reduced pressure. The solid 
obtained was purified by crystallization from Et2O–hexane (2:1) to 
give pure 6 as white crystals.  
7.30 g (35.6 mmol, 89%); Mp: 108–109 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.07–7.02 (m, 4 H, H-3, H-4, H-
5 and H-6), 5.65 (br, exch., 1 H, NH), 4.29 (d, J = 5 Hz, 2 H, 
CH2), 2.17 (s, 3 H, CH3), 1.09 [s, 9 H, C(CH3)3]. 
13C NMR (100 MHz, CDCl3): δ = 178.5 (C=O), 136.9 (C-1), 
136.6 (C-2), 130.9 (C-3), 128.8 (C-6), 128.1 (C-4), 126.6 (C-5), 
42.3 (CH2), 39.2 [C(CH3)3], 28.0 [C(CH3)3], 19.3 (CH3). 
MS (EI): m/z (%) = 205 (17) [M]+, 105 (78), 91 (23), 77 (30), 57 
(100). 
MS (CI): m/z (%) = 411 (16) [2 M + 1]+, 223 (24) [M + NH4]+, 
206 (100) [MH]+. 
HRMS-CI: m/z [MH]+ calcd for C13H20NO: 206.1539; found: 
206.1542. 
IR (FT): 3316, 2959, 1637, 1538, 1221, 1005 cm-1. 
 
N-(2-Substituted methyl)benzylamines 9-14 and 15-22 
A solution of t-BuLi in heptane (2.6 mL, 1.7 M, 4.4 mmol) was 
added to a cold (-78 °C), stirred solution of 5 or 6 (2.0 mmol) in 
anhydrous THF (20 mL) under N2. The mixture was stirred at 
-78 °C for 4 h, to ensure the complete formation of the dilithium 
reagent, after which an electrophile (2.2 mmol), in anhydrous THF 
(8 mL) if solid, otherwise neat, was added. The mixture was 
stirred for 2 h at –78 °C then the cooling bath was removed and 
the mixture allowed to warm to room temperature. It was then 
diluted with Et2O (10 mL) and quenched with aq. sat. NH4Cl (10 
mL). The organic layer was separated, washed with H2O (2 x 10 
mL), dried (MgSO4), and evaporated under reduced pressure. The 
residue obtained was purified by column chromatography (silica 
gel; Et2O-hexane, 1:3) to give pure product as a white solid. The 
yields obtained are recorded in Tables 1 and 2. 
 
N'-(2-(2-Hydroxy-2-phenylethyl)benzyl)-N,N-dimethylurea (9) 
0.46 g (1.54 mmol, 77%); Mp 116–117 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.27–7.12 (m, 10 H, Ph, H-3, H-
4, H-5, H-6 and NH), 5.44 (br s, exch., 1 H, OH), 4.82 (dd, J = 4, 
9 Hz, 1 H, CH), 4.33 (d, J = 14 Hz, 1 H, CHaHbNH), 4.25 (d, J = 
14 Hz, 1 H, CHaHbNH), 3.02 (dd, J = 9, 14 Hz, 1 H, CHaHbCH), 
2.88 (dd, J = 4, 14 Hz, 1 H, CHaHbCH), 2.75 [s, 6 H, N(CH3)2]. 
13C NMR (100 MHz, CDCl3): δ = 158.9 (C=O), 144.8 (C-1), 
138.5 (C-1 of Ph), 137.7 (C-2), 130.7 (C-3), 130.4 (C-6), 128.9 
(C-3/C-5 of Ph), 128.1 (C-4), 128.0 (C-5), 127.3 (C-4 of Ph), 
126.2 (C-2/C-6 of Ph), 76.1 (CH), 43.3 (CH2), 42.5 (CH2), 36.6 
[N(CH3)2].  
MS (EI): m/z (%) = 299 (6) [M + 1]+, 298 (1) [M]+, 281 (51), 280 
(14), 209 (33), 208 (100). 
MS (CI): m/z (%) = 316 (3) [M + NH4]+, 299 (100) [MH]+, 282 
(26), 281 (100), 193 (44), 179 (12), 106 (41), 89 (64), 52 (68), 46 
(78). 
HRMS-CI: m/z [MH]+ calcd for C18H23N2O2:299.1754; found: 
299.1755.  
IR (FT): 3230, 2938, 16310, 1586, 1530, 1212, 1018 cm-1.  
Anal. Calcd for C18H22N2O2: C, 72.46; H, 7.43; N, 9.39. Found: C, 
72.50; H, 7.47; N, 9.40. 
 
N'-(2-(2-(Hydroxy-2-(4-methoxyphenyl)ethyl)benzyl)-N,N-
dimethylurea (10) 
0.52 g (1.58 mmol, 79%); Mp 108–109 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.31 (d, J = 9 Hz, 2 H, H-2/H-6 
of 4-methoxyphenyl), 7.29–7.22 (m, 5 H, H-3, H-4, H-5, H-6 and 
NH), 6.89 (d, J = 9 Hz, 2 H, H-3/H-5 of 4-methoxyphenyl), 5.32 
(s, exch., 1 H, OH), 4.88 (dd, J = 4, 9 Hz, 1 H, CH), 4.44 (d, J = 
14 Hz, 1 H, CHaHbNH), 4.35 (d, J = 14 Hz, 1 H, CHaHbNH), 3.81 
(s, 3 H, OCH3), 3.12 (dd, J = 9, 14 Hz, 1 H, CHaHbCH), 2.94 (dd, 
J = 4, 14 Hz, 1 H, CHaHbCH), 2.85 [s, 6 H, N(CH3)2]. 
13C NMR (100 MHz, CDCl3): δ = 159.4 (C=O), 158.9 (C-4 of 
4-methoxyphenyl), 138.4 (s, C-1), 137.8 (s, C-2), 137.0 (s, C-1 of 
4-methoxyphenyl), 130.7 (C-3), 130.4 (C-6), 128.1 (C-4), 127.4 
(C-2/C-6 of 4-methoxyphenyl), 127.3 (C-5), 114.2 (C-3/C-5 of 4-
methoxyphenyl), 75.7 (CH), 55.7 (OCH3), 43.3 (CH2), 42.5 (CH2), 
36.6 [N(CH3)2]. 
MS (EI): m/z (%) = 328 (2) [M]+, 311 (100), 310 (51), 308 (20), 
265 (63). 
MS (CI): m/z (%) = 328 (3) [M]+, 327 (3), 312 (17), 311 (100), 
240 (11), 193 (28), 179 (14), 154 (28), 137 (22), 135 (17), 106 
(58), 89 (81), 63 (20). 
MS (ES+): m/z (%) = 351 (58) [M + Na]+, 329 (2) [MH]+, 312 
(22), 311 (100). 
MS (ES–): m/z (%) = 328 (14) [M]–, 327 (100). 
HRMS-CI: m/z [MH]+ calcd for C19H25N2O3: 329.1860; found: 
329.1864. 
IR (FT): 3314, 2933, 1632, 1530, 1510, 1243, 1024 cm-1. 
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N'-(2-(2-Hydroxy-2-phenylpropyl)benzyl)-N,N-dimethylurea 
(11) 
0.45 g (1.47 mmol, 74%); Mp 82–83 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.33 (d, J = 8 Hz, 2 H, H-2/H-6 
of Ph), 7.26–7.22 (m, 3 H, H-3/H-5 and H-4 of Ph), 7.17 (d, J = 8 
Hz, 1 H, H-3), 7.14 (br, exch., 1 H, NH), 7.08 (app. t, J = 8 Hz, 1 
H, H-5), 6.99 (app. t, J = 8 Hz, 1 H, H-4), 6.74 (d, J = 8 Hz, 1 H, 
H-6), 5.35 (s, exch., 1 H, OH), 4.31 (d, J = 14 Hz, 1 H, 
CHaHbNH), 4.23 (d, J = 14 Hz, 1 H, CHaHbNH), 3.09 (d, J = 14 
Hz, 1 H, CHaHbCOH), 3.04 (d, J = 14 Hz, 1 H, CHaHbCOH), 2.78 
[s, 6 H, N(CH3)2], 1.6 (s, 3 H, CH3). 
13C NMR (100 MHz, CDCl3): δ = 158.9 (C=O), 148.5 (C-1 of Ph), 
139.6 (C-1), 135.8 (C-2), 132.3 (C-3), 130.2 (C-6), 128.5 (C-3/C-
5 of Ph), 127.4 (C-4 of Ph), 127.1 (C-5), 126.5 (C-4), 125.4 (C-
2/C-6 of Ph), 75.4 (C-OH), 46.6 (CH2), 43.2 (CH2), 36.7 
[N(CH3)2], 30.3 (CH3). 
MS (EI): m/z (%) = 312 (1) [M]+, 295 (12), 294 (10), 222 (25), 
207 (32), 206 (100). 
MS (CI): m/z (%) = 313 (33) [MH]+, 297 (24), 296 (20), 295 
(100), 235 (13), 193 (78), 179 (9), 138 (39), 106 (42), 89 (78), 52 
(58), 46 (67), 44 (24). 
HRMS-CI: m/z [MH]+ calcd for C19H25N2O2: 313.1911; found: 
313.1912. 
IR (FT): 3329, 2928, 1611, 1531, 1246, 1026 cm-1. 
 
N'-(2-(2-Hydroxy-2,2-diphenylethyl)benzyl)-N,N-dimethylurea 
(12) 
0.57 g (1.52 mmol, 76%); Mp 119–120 °C.  
1H NMR (400 MHz, DMSO-d6): δ = 7.41 (d, J = 8 Hz, 4 H, H-
2/H-6 of 2 Ph), 7.27 (app. t, J = 8 Hz, 4 H, H-3/H-5 of 2 Ph), 
7.19–6.86 (m, 6 H, H-3, H-4, H-5, H-6 and H-4 of 2 Ph), 6.66 (t, J 
= 6 Hz, exch., 1 H, NH), 5.83 (s, exch., 1 H, OH), 3.99 (d, J = 6 
Hz, 2 H, CH2NH), 3.68 (s, 2 H, CH2COH), 2.79 [s, 6 H, N(CH3)2]. 
13C NMR (100 MHz, DMSO-d6): δ = 158.5 (C=O), 148.5 (C-1 of 
2 Ph), 140.9 (C-1), 135.4 (C-2), 131.8 (C-3), 128.0 (C-6), 127.9 
(C-3/C-5 of 2 Ph), 126.8 (C-2/C-6 of 2 Ph), 126.6 (C-4 of 2 Ph), 
126.0 (C-4), 125.4 (C-5), 77.8 (C-OH), 42.9 (CH2), 41.3 (CH2), 
36.3 [N(CH3)2]. 
MS (EI): m/z (%) = 374 (2) [M]+, 357 (11), 268 (100), 252 (16), 
239 (12), 206 (25). 
MS (CI): m/z (%) = 375 (12) [MH]+, 374 (6) [M]+, 373 (5), 359 
(33), 357 (89), 286 (10), 257 (12), 200 (81), 193 (100), 183 (71), 
179 (17), 118 (24), 106 (55), 89 (87), 63 (15). 
MS (ES+): m/z (%) = 397 (100) [M + Na]+, 375 (4) [MH]+, 358 
(13), 357 (69), 270 (14), 269 (52), 191(34), 89 (78). 
MS (ES–): m/z (%) = 374 (2) [M]–, 373 (8), 191 (100), 146 (9), 
118 (21), 87 (25). 
HRMS-CI: m/z [M + NH4]+ calcd for C24H30N3O2: 392.2333; 
found: 392.2330. 
IR (FT): 3331, 2927, 1621, 1531, 1246, 1026 cm-1. 
 
N'-(2-Propylbenzyl)-N,N-dimethylurea (13) 
0.36 g (1.64 mmol, 82%); Mp 59–61 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.20–7.05 (m, 4 H, H-3, H-4, H-
5 and H-6), 4.58 (br, exch., 1 H, NH), 4.33 (br, 2 H, CH2NH), 2.80 
[s, 6 H, N(CH3)2], 2.54 (t, J = 7 Hz, 2 H, CH2CH2CH3), 1.53 (app. 
sextet, J = 7 Hz, 2 H, CH2CH3), 0.89 (t, J = 7 Hz, 3 H, CH2CH3). 
13C NMR (100 MHz, CDCl3): δ = 158.6 (C=O), 141.3 (C-1), 
137.1 (C-2), 129.9 (C-3), 129.1 (C-6), 127.8 (C-4), 126.5 (C-5), 
42.9 (CH2NH), 36.6 [N(CH3)2], 34.9 (CH2CH2CH3), 24.8 
(CH2CH3), 14.5 (CH2CH3). 
MS (EI): m/z (%) = 220 (31) [M]+, 177 (13), 148 (10), 132 (47), 
117 (82), 105 (53), 91 (22), 89 (34), 77 (24), 72 (100), 65 (15), 46 
(23), 44 (69), 42 (33). 
MS (CI): m/z (%) = 441 (12) [2 M + 1]+, 238 (13) [M + NH4]+, 
221 (100) [MH]+. 
HRMS-CI: m/z [MH]+ calcd for C13H21N2O: 221.1648; found: 
221.1648. 
IR (FT): 3325, 2957, 1631, 1529, 1375, 1227 cm-1. 
 
N'-(2-Deuteriomethylbenzyl)-N,N-dimethylurea (14) 
0.32 g (1.66 mmol, 83%); Mp 73–75 °C (Mp of undeuteriated 
analogue 73–75 °C28). 
1H NMR (400 MHz, CDCl3): δ = 7.26–7.12 (m, 4 H, H-3, H-4, H-
5 and H-6), 4.61 (br, exch., 1 H, NH), 4.42 (br, 2 H, CH2NH), 2.91 
[s, 6 H, N(CH3)2], 2.31 (seen as three lines, 1:1:1, because of 
coupling to D, 2 H, CH2D). 
13C NMR (100 MHz, CDCl3): δ = 158.7 (C=O), 137.5 (C-1), 
136.8 (C-2), 130.8 (C-6), 128.7 (C-3), 127.8 (C-5), 126.5 (C-4), 
43.6 (CH2NH), 36.6 [N(CH3)2], 19.4 (seen as three lines, 1:1:1, 
because of coupling to D, CH2D). 
MS (EI): m/z (%) = 194 (15) [M + 1]+, 193 (43), 149 (11), 121 
(37), 106 (71), 105 (66), 92 (21), 78 (24), 77 (21), 72 (100), 46 
(32), 44 (79), 42 (27). 
MS (CI): m/z (%) = 211 (17) [M + NH4]+, 195 (23), 194 (100) 
[MH]+, 52 (20). 
HRMS-CI: m/z [MH]+ calcd for C11H16DN2O: 194.1398; found: 
194.1398. 
IR (FT): 3315, 2926, 1622, 1537, 1512, 1376, 12.35, 1027 cm-1. 
 
N-(2-(2-Hydroxy-2-phenyethyl)benzyl)pivalamide (15) 
0.52 g (1.67 mmol, 84%); Mp 133–134 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.42–7.21 (m, 9 H, Ph, H-3, H-
4, H-5 and H-6), 6.69 (br app. t, exch., 1 H, NH), 4.94 (dd, 1 H, J 
= 9, 4 Hz, CH), 4.53 (dd, J = 6, 14 Hz, 1 H, CHaHbNH), 4.33 (dd, 
J = 2, 14 Hz, 1 H, CHaHbNH), 3.10 (dd, J = 9, 14 Hz, 1 H, 
CHaHbCH), 3.01 (dd, J = 4, 14 Hz, 1 H, CHaHbCH), 2.78 (br, 
exch., 1 H, OH), 1.19 [s, 9 H, C(CH3)3]. 
13C NMR (100 MHz, CDCl3): δ = 178.7 (C=O), 144.6 (C-1), 
137.7 (C-1 of Ph), 137.6 (C-2), 130.8 (C-3), 130.3 (C-6), 128.9 
(C-3/C-5 of Ph), 128.3 (C-4 of Ph), 128.1 (C-4), 127.4 (C-5), 
126.2 (C-2/C-6 of Ph), 76.2 (CH), 42.5 (CH2), 41.8 (CH2), 39.1 
[C(CH3)3], 28.0 [C(CH3)3]. 
MS (EI): m/z (%) = 311 (6) [M]+, 295 (31), 294 (100), 278 (8). 
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MS (CI): m/z (%) = 329 (9) [M + NH4]+, 313 (13) [MH + 1]+, 312 
(78) [MH]+, 294 (100), 234 (8), 206 (12), 205 (17), 192 (7), 119 
(10), 102 (9). 
HRMS-CI: m/z [MH]+ calcd for C20H26NO2: 312.1958; found: 
312.1955. 
IR (FT): 3314, 2971, 1627, 1542, 1367, 1216, 1055 cm-1. 
Anal. Calcd for C20H25NO2: C, 77.14; H, 8.09; N, 4.50. Found: C, 
77.21; H, 8.14; N, 4.54. 
 
N-(2-(2-Hydroxy-2-(4-methoxyphenyl)ethyl)benzyl)pivalamide 
(16) 
0.61 g (1.79 mmol, 89%); Mp 124–126 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.29 (d, J = 9 Hz, 2 H, H-2/H-6 
of 4-methoxyphenyl), 7.28–7.20 (m, 4 H, H-3, H-4, H-5 and H-6), 
6.88 (d, J = 9 Hz, 2 H, H-3/H-5 of 4-methoxyphenyl), 6.83 (br, 
exch., 1 H, NH), 4.87 (dd, J = 4, 9 Hz, 1 H, CH), 4.49 (dd, J = 6, 
14 Hz, 1 H, CHaHbNH), 4.30 (dd, J = 4, 14 Hz, 1 H, CHaHbNH), 
3.80 (s, 3 H, OCH3), 3.22 (br, exch., 1 H, OH), 3.07 (dd, J = 9, 14 
Hz, 1 H, CHaHbCH), 2.94 (dd, J = 4, 14 Hz, 1 H, CHaHbCH), 1.17 
[s, 9 H, C(CH3)3]. 
13C NMR (100 MHz, CDCl3): δ = 178.8 (C=O), 159.4 (C-4 of 
4-methoxyphenyl), 137.9 (C-1), 137.5 (C-2), 137.0 (C-1 of 
4-methoxyphenyl), 130.8 (C-3), 130.2 (C-6), 128.2 (C-4), 127.6 
(C-2/C-6 of 4-methoxyphenyl), 127.3 (C-5), 114.2 (C-3/C-5 of 
4-methoxyphenyl), 75.7 (CH), 55.7 (OCH3), 42.5 (CH2), 41.9 
(CH2), 39.01 [C(CH3)3], 28.0 [C(CH3)3]. 
MS (EI): m/z (%) = 341 (5) [M]+, 324 (63), 323 (79), 308 (5), 266 
(21), 254 (13), 238 (100). 
MS (CI): m/z (%) = 357 (4) [M + NH4]+, 342 (8) [MH]+, 341 (20) 
[M]+, 325 (24), 324 (100), 251 (4), 234 (6), 205 (7), 154 (8), 119 
(15), 102 (7), 52 (10). 
MS (ES+): m/z (%) = 364 (19) [M + Na]+, 324 (33), 223 (100). 
MS (ES–): m/z (%) = 340 (12) [M – 1]–, 205 (12) 204 (100), 100 
(28). 
HRMS-CI: m/z [MH]+ calcd for C21H28NO3: 342.2064; found: 
342.2065. 
IR (FT): 3321, 2954, 1629, 1555, 1463, 1370, 1220, 1035 cm-1. 
 
N-(2-(2-Hydroxy-2-phenylpropyl)benzyl)pivalamide (17) 
0.52 g (1.60 mmol, 80%); Mp 135–137 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.43 (d, J = 8 Hz, 2 H, H-2/H-6 
of Ph), 7.35 (t, J = 8 Hz, 2 H, H-3/H-5 of Ph), 7.30–7.26 (m, 2 H, 
H-4 of Ph and H-6), 7.20 (app. dt, J = 2, 8 Hz, 1 H, H-4), 7.12 
(app. dt, J = 2, 8 Hz, 1 H, H-5), 6.87 (dd, J = 2, 8 Hz, 1 H, H-3), 
6.55 (br app. t, exch., 1 H, NH), 4.44 (dd, J = 5, 14 Hz, 1 H, 
CHaHbNH), 4.37 (dd, J = 5, 14 Hz, 1 H, CHaHbNH), 3.17 (d, J = 
14 Hz, 1 H, CHaHbCOH), 3.12 (d, J = 14 Hz, 1 H, CHaHbCOH), 
2.42 (s, exch., 1 H, OH), 1.68 (s, 3 H, CH3COH), 1.21 [s, 9 H, 
C(CH3)3]. 
13C NMR (100 MHz, CDCl3): δ = 178.6 (C=O), 149.2 (C-1 of Ph), 
138.7 (C-1), 135.8 (C-2), 132.4 (C-3), 130.0 (C-6), 128.5 (C-3/C-
5 of Ph), 127.5 (C-4), 127.3 (C-4 of Ph), 127.2 (C-2/C-6 of Ph), 
125.4 (C-5), 75.5 (C-OH), 46.6 (CH2), 41.7 (CH2), 39.1 
[C(CH3)3], 30.3 (CH3COH), 29.5 [C(CH3)3]. 
MS (EI): m/z (%) = 325 (1) [M]+, 308 (77), 307 (34), 292 (12), 
282 (23), 264 (31), 248 (19), 229 (60), 222 (100). 
MS (CI): m/z (%) = 343 (2) [M + NH4]+, 326 (34) [MH]+, 309 
(36), 308 (100), 248 (5), 306 (17), 205 (22), 138 (7), 119 (9), 102 
(9), 52 (7). 
HRMS-CI: m/z [MH+] calcd for C21H28NO2: 326.2115; found: 
326.2115. 
IR (FT): 3324, 2964, 1623, 1493, 1242, 1025 cm-1. 
 
N-(2-(2-Hydroxy-2,2-diphenylethyl)benzyl)pivalamide (18) 
0.68 g (1.76 mmol, 88%); M.p: 94–95 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.42–7.23 (m, 11 H, 2 Ph and H-
6), 7.17 (app. dt, J = 2, 8 Hz, 1 H, H-4), 6.97 (app. dt, J = 2, 8 Hz, 
1 H, H-5), 6.56 (dd, J = 2, 8 Hz, 1 H, H-3), 6.38 (br t, exch., 1 H, 
NH), 4.36 (d, J = 5 Hz, 2 H, CH2NH), 3.75 (s, 2 H, CH2COH), 
2.72 (s, exch., 1 H, OH), 1.18 [s, 9 H, C(CH3)3]. 
13C NMR (CDCl3): δ = 178.6 (100 MHz, C=O), 147.1 (C-1 of 2 
Ph), 139.0 (C-1), 134.8 (C-2), 132.3 (C-3), 129.7 (C-6), 128.5 (C-
4), 128.3 (C-3/C-5 of 2 Ph), 127.6 (C-4 of 2 Ph), 127.2 (C-5), 
126.8 (C-2/C-6 of 2 Ph), 79.0 (C-OH), 43.8 (CH2), 42.3 (CH2), 
39.1 [C(CH3)3], 29.5 [C(CH3)3]. 
MS (EI): m/z (%) = 370 (7), 284 (12), 269 (39), 268 (100), 252 
(13). 
MS (CI): m/z (%) = 405 (5) [M + NH4]+, 388 (18) [MH]+, 387 (33) 
[M]+, 370 (100), 310 (11), 285 (5), 257 (7), 223 (12), 206 (41), 
200 (52), 183 (17), 119 (29), 102 (12), 52 (16). 
ES+–MS: m/z (%) = 410 (23) [M + Na]+, 370 (72), 270 (22), 269 
(100), 191 (47), 102 (49), 91 (47). 
MS (ES–): m/z (%) = 388 (3) [MH]–, 387 (21) [M]–, 386 (100). 
HRMS-CI: m/z [M + NH4]+ calcd for C26H33N2O2: 405.2537; 
found: 405.2534.  
IR (FT): 3310, 2933, 1635, 1531, 1449, 1227, 1020 cm-1. 
 
N-(2-((1-Hydroxycyclohexyl)methyl)benzyl)pivalamide (19) 
0.46 g (1.52 mmol, 76%); Mp 93–96 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.23-7.09 (m, 4 H, H-3, H-4, H-
5 and H-6), 6.77 (br t, exch., 1 H, NH), 4.41 (br d, 2 H, CH2NH), 
2.75 (s, 2 H, CH2COH), 1.86 (br s, exch., 1 H, OH), 1.51-1.43 [m, 
10 H, (CH2)5], 1.10 [s, 9 H, C(CH3)3]. 
13C NMR (100 MHz, CDCl3): δ = 178.7 (C=O), 138.6 (C-1), 
136.3 (C-2), 132.3 (C-3), 130.3 (C-6), 127.4 (C-4), 127.3 (C-5), 
72.2 (C-1 of cyclohexyl), 45.0 (CH2NH), 42.2 (CH2COH), 39.1 
[C(CH3)3], 38.3 (C-2/C-6 of cyclohexyl), 28.0 [C(CH3)3], 26.1 (C-
4 of cyclohexyl), 22.4 (C-3/C-5 of cyclohexyl). 
MS (EI): m/z (%) = 303 (7) [M]+, 286 (39), 285 (87), 270 (12), 
260 (100), 242 (40), 228 (77), 218 (71). 
MS (CI): m/z (%) = 321 (3) [M + NH4]+, 304 (100) [MH]+, 286 
(58), 205 (9), 119 (5), 52 (11). 
HRMS-CI: m/z [MH]+ calcd for C19H30NO2: 304.2271; found: 
304.2272. 
IR (FT): 3341, 2929, 1634, 1529, 1449, 1208 cm-1. 
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N-(2-Ethylbenzyl)pivalamide (20) 
0.38 g (1.74 mmol, 87%); Mp: 64–65 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.18–7.08 (m, 4 H, H-3, H-4, H-
5 and H-6), 5.69 (br t, exch., 1 H, NH), 4.37 (d, J = 5 Hz, 2 H, 
CH2NH), 2.58 (q, J = 7 Hz, 2 H, CH2CH3), 1.14 (t, J = 7 Hz, 3 H, 
CH2CH3), 1.13 [s, 9 H, C(CH3)3]. 
13C NMR (100 MHz, CDCl3): δ = 178.5 (C=O), 143.0 (C-1), 
135.9 (C-2), 129.3 (C-3), 129.2 (C-6), 128.4 (C-4), 126.6 (C-5), 
41.8 (CH2NH), 39.1 [C(CH3)3], 28.0 [C(CH3)3], 25.7 (CH2CH3), 
15.8 (CH2CH3). 
MS (ES+): m/z (%) = 237 (15) [M + NH4]+, 220 (100) [MH]+. 
HRMS-ES+: m/z [MH]+ calcd for C14H22NO: 220.1696; found: 
220.1694.  
IR (FT): 3331, 2963, 1632, 1531, 1217, 1008 cm-1. 
 
N-(2-Propylbenzyl)pivalamide (21) 
0.41 g (1.76 mmol, 88%); Mp 66–67 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.18–7.08 (m, 4 H, H-3, H-4, H-
5 and H-6), 5.68 (br t, exch., 1 H, NH), 4.37 (d, J = 5 Hz, 2 H, 
CH2NH), 2.52 (t, J = 7 Hz, 2 H, CH2CH2CH3), 1.53 (app. sextet, J 
= 7 Hz, 2 H, CH2CH3), 1.14 [s, 9 H, C(CH3)3], 0.98 (t, J =7 Hz, 3 
H, CH2CH3). 
13C NMR (100 MHz, CDCl3): δ = 178.4 (C=O), 141.5 (C-1), 
136.1 (C-2), 130.1 (C-3), 129.2 (C-6), 128.1 (C-4), 126.6 (C-5), 
41.8 (CH2NH), 39.1 [C(CH3)3], 34.9 (CH2CH2CH3), 28.0 
[C(CH3)3], 24.8 (CH2CH3), 15.8 (CH2CH3). 
MS (EI): m/z (%) = 233 (9) [M]+, 204 (5), 190 (4), 133 (14), 132 
(97), 117 (100), 105 (81), 91 (24), 57 (49). 
MS (CI): m/z (%) = 251 (45) [M + NH4]+, 334 (100) [MH]+, 206 
(18), 132 (20), 119 (8), 102 (6). 
MS (ES+): m/z (%) = 251 (7) [M + NH4]+, 234 (42) [MH]+, 133 
(17), 114 (18), 106 (32), 105 (100), 104 (95). 
HRMS-CI: m/z [MH]+ calcd for C15H24NO: 234.1852; found: 
234.1852. 
IR (FT): 3331, 2963, 1633, 1530, 1363, 1218, 1008 cm-1. 
 
N-(2-Deuteriomethylbenzyl)pivalamide (22) 
0.35 g (1.70 mmol, 85%); Mp 108–109 °C (Mp of undeuteriated 
analogue 108–109 °C28).  
1H NMR (400 MHz, CDCl3): δ = 7.13–7.09 (m, 4 H, H-3, H-4, H-
5 and H-6), 5.70 (br t, exch., 1 H, NH), 4.34 (d, J = 5 Hz, 2 H, 
CH2NH), 2.21 (seen as three lines, 1:1:1, because of coupling to 
D, 2 H, CH2D), 1.14 [s, 9 H, C(CH3)3]. 
13C NMR (100 MHz, CDCl3): δ = 178.5 (C=O), 136.9 (C-1), 
136.5 (C-2), 131.0 (C-3), 128.8 (C-6), 128.1 (C-4), 126.6 (C-5), 
42.3 (CH2NH), 39.2 [C(CH3)3], 28.1 [C(CH3)3], 19.1 (seen as 
three lines, 1:1:1, because of coupling to D, CH2D). 
MS (EI): m/z (%) = 207 (4) [M + 1]+, 206 (13) [M]+, 109 (2), 107 
(20), 106 (60), 105 (37), 92 (10), 78 (12), 57 (92). 
MS (CI): m/z (%) = 224 (12) [M + NH4]+, 208 (32) [MH + 1]+, 
207 (100) [MH]+. 
HRMS-CI: m/z [MH]+ calcd for C13H19DNO: 207.1602; found: 
207.1602. 
IR (FT): 3328, 2924, 1612, 1532, 1238, 1024 cm-1. 
 
Synthesis of 23-29 
Trifluoroacetic anhydride (0.5 mL, excess) was added to a stirred 
solution of the appropriate substituted benzylamine 9-12 or 15-17 
(0.50 g) in DCM (10 mL) at room temperature. The mixture was 
stirred for 5 min at room temperature (1 h in the case of compound 
17). The reaction mixture was quenched with H2O (10 mL). The 
organic layer was separated, washed with aq. sat. NaHCO3 (10 
mL) and H2O (2 x 10 mL), dried (MgSO4), and evaporated under 
reduced pressure. The residue obtained was subjected to flash 
column chromatography (silica gel; Et2O–hexane, 1:3) to give 
pure the product. 
 
2-Dimethylaminocarbonyl-3-phenyl-1,2,3,4-tetrahydroiso-
quinoline (23) 
0.44 g (94%); Mp 96–98 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.27–7.08 (m, 9 H, H-5, H-6, H-
7, H-8 and Ph), 4.78 (dd, J = 4, 9 Hz, 1 H, H-3), 4.31 (d, J = 14 
Hz, 1 H, H-1a), 4.21 (d, J = 14 Hz, 1 H, H-1b), 2.96 (dd, J = 9, 14 
Hz, 1 H, H-4a), 2.83 (dd, J = 4, 14 Hz, 1 H, H-4b), 2.72 [s, 6 H, 
N(CH3)2].  
13C NMR (100 MHz, CDCl3): δ = 158.8 (C=O), 144.5 (C-4a), 
137.9 (C-8a), 137.2 (C-1 of Ph), 130.0 (C-8), 129.6 (C-4 of Ph), 
129.3 (C-3/C-5 of Ph), 128.9 (C-5), 128.2 (C-6), 127.5 (C-7), 
126.9 (C-2/C-6 of Ph), 76.3 (C-3), 43.5 (C-1), 42.6 (C-4), 38.1 
[N(CH3)2].  
MS (EI): m/z (%) = 280 (2) [M]+, 208 (4), 192 (44), 177 (6), 148 
(7), 120 (18), 104 (100), 91 (25), 77 (61), 72 (66), 44 (26). 
MS (CI): m/z (%) = 299 (62) [M + NH4]+, 281 (72) [MH]+, 271 
(9), 193 (22), 179 (15), 118 (16), 106 (32), 89 (36), 72 (7), 63 
(12), 46 (100). 
HRMS-CI: m/z [MH]+ calcd for C18H21N2O: 281.1648; found: 
281.1647.  
FT–IR: 2935, 1636, 1523, 1512, 1455, 1203, 1174, 1037 cm-1. 
 
2-Dimethylaminocarbonyl-3-(4-methoxyphenyl)-1,2,3,4-
tetrahydroisoquinoline (24) 
0.45 g (95%); Mp 102–103 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.18–7.07 (m, 3 H, H-6, H-7 and 
H-8), 7.04 (d, J = 9 Hz, 2 H, H-2/H-6 of 4-methoxyphenyl), 6.90 
(d, J = 8 Hz, 1 H, H-5), 6.69 (d, J = 9 Hz, 2 H, H-3/H-5 of 4-
methoxyphenyl), 5.18 (dd, J = 3, 6 Hz, 1 H, H-3), 4.34 (d, J = 16 
Hz, 1 H, H-1a), 4.00 (d, J = 16 Hz, 1 H, H-1b), 3.65 (s, 3 H, 
OCH3), 3.36 (dd, J = 6, 16 Hz, 1 H, H-4a), 3.13 (dd, J = 3, 16 Hz, 
1 H, H-4b), 2.80 [s, 6 H, N(CH3)2]. 
13C NMR (100 MHz, CDCl3): δ = 165.2 (C=O), 158.9 (C-4 of 
4-methoxyphenyl), 134.3 (C-4a), 133.1 (C-8a), 129.1 (C-1 of 4-
methoxyphenyl), 128.7 (C-8), 128.4 (C-2/C-6 of 
4-methoxyphenyl), 127.2 (C-5), 126.4 (C-6), 126.2 (C-7), 114.1 
(C-3/C-5 of 4-methoxyphenyl), 55.6 (OCH3), 54.0 (C-3), 46.3 (C-
1), 39.0 [N(CH3)2], 32.2 (C-4). 
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MS (EI): m/z (%) = 310 (12) [M]+, 266 (9), 238 (32), 222 (62), 
202 (15), 189 (23), 178 (11), 165 (13), 121 (31), 104 (100), 91 
(17), 72 (93), 44 (17). 
MS (CI): m/z (%) = 311 (100) [MH]+, 89 (17), 52 (33), 46 (28). 
HRMS-CI: m/z [MH]+ calcd for C19H23N2O2: 311.1754; found: 
311.1751. 
FT–IR: 2958, 1618, 1510, 1399, 1370, 1348, 1242, 1173, 1033 
cm-1. 
 
2-Dimethylaminocarbonyl-3-methyl-3-phenyl-1,2,3,4-
tetrahydroisoquinoline (25) 
0.43 g (91%); Mp 122–124 °C. 
1H NMR (400 MHz, CDCl3): δ = 7.30–7.04 (m, 8 H, H-6, H-7, H-
8 and Ph), 6.89 (d, J = 8 Hz, 1 H, H-5), 4.28 (d, J = 16 Hz, 1 H, H-
1a), 4.14 (d, J = 16 Hz, H-1b), 3.42 (d, J = 16 Hz, 1 H, H-4a), 3.23 
(d, J = 16 Hz, 1 H, H-4b), 2.82 [s, 6 H, N(CH3)2], 1.59 (s, CH3C). 
13C NMR (100 MHz, CDCl3): δ = 164.6 (C=O), 147.7 (C-1 of Ph), 
135.6 (C-4a), 134.1 (C-8a), 129.4 (C-5), 128.8 (C-3/C-5 of Ph), 
127.9 (C-6), 127.1 (C-7), 126.5 (C-4 of Ph), 125.6 (C-8), 125.5 
(C-2/C-6 of Ph), 59.4 (C-3), 49.8 (C-4), 43.6 (C-1), 39.8 
[N(CH3)2], 28.1 (CH3C). 
MS (EI): m/z (%) = 294 (22) [M]+, 279 (24), 222 (52), 206 (100). 
MS (CI): m/z (%) = 295 (100) [MH]+, 222 (7), 193 (8), 89 (12), 52 
(28), 46 (52). 
HRMS-CI: m/z [MH]+ calcd for C19H23N2O: 295.1805; found: 
295.1807. 
FT–IR: 2973, 1645, 1522, 1492, 1381, 1361, 1174, 1107 cm-1. 
 
N'-(2-(2,2-Diphenylethenyl)benzyl)-N,N-dimethylurea (26) 
0.45 g (95%); Mp 106–108 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.39–7.05 (m, 13 H, H-5, H-6, 
CH and 2 Ph), 6.87 (app. t, J = 8 Hz, 1 H, H-4), 6.83 (t, J = 6 Hz, 
exch., 1 H, NH), 6.71 (d, J = 8 Hz, 1 H, H-3), 4.31 (d, J = 6 Hz, 2 
H, CH2), 2.77 [s, 6 H, N(CH3)2].  
13C NMR (100 MHz, CDCl3): δ = 158.4 (C=O), 143.0 (C-1 of 2 
Ph), 142.9 (C=CH), 140.0 (C-1), 136.0 (C-2), 130.7 (C-3/C-5 of 2 
Ph), 129.7 (C-3), 128.7 (C-4 of 2 Ph), 128.6 (C-4), 127.9 (C-2/C-6 
of 2 Ph), 127.6 (C-5), 127.0 (C-6), 126.1 (C=CH), 42.2 (CH2), 
36.2 [N(CH3)2].  
MS (EI): m/z (%) = 356 (12) [M]+, 312 (7), 284 (10), 268 (100), 
252 (8), 206 (12), 178 (13), 167 (33), 152 (18), 91 (13), 72 (71), 
44 (22). 
MS (CI): m/z (%) = 374 (100) [M + NH4]+, 357 (81) [MH]+, 331 
(6), 301 (5), 276 (7), 167 (15), 118 (19), 106 (25), 89 (33), 46 
(100). 
HRMS-CI: m/z [MH]+ calcd for C24H25N2O: 357.1961; found: 
357.1960.  
FT–IR: 3316, 2958, 1637, 1538, 1352, 1230 cm-1. 
Anal. Calcd for C24H24N2O: C, 80.87; H, 6.79; N, 7.86. Found: C, 
80.90; H, 6.89; N, 7.63. 
 
 
N-(2-(2-Phenyl-2-trifluoroacetoxyethyl)benzyl)pivalamide (27) 
0.63 g (97%); Mp 127–128 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.32–7.07 (m, 9 H, H-3, H-4, H-
5, H-6 and Ph), 6.01 (dd, J = 6, 8 Hz, 1 H, CH), 5.80 (br app. t, 
exch., 1 H, NH), 4.38 (dd, J = 6, 15 Hz, 1 H, CHaHbNH), 4.29 (dd, 
J = 6, 15 Hz, 1 H, CHaHbNH), 3.24 (dd, J = 8, 15 Hz, 1 H, 
CHaHbCH), 3.19 (dd, J = 6, 15 Hz, 1 H, CHaHbCH), 1.13 [s, 9 H, 
C(CH3)3].  
13C NMR (100 MHz, CDCl3): δ = 178.7 (C=O), 156.9 (seen as a 
quartet because of coupling to F, CF3C=O), 137. 8 (C-1), 137.1 
(C-1 of Ph), 134.5 (C-2), 131.6 (C-3), 129.9 (C-4), 129.5 (C-5), 
129.4 (C-6), 129.3 (C-3/C-5 of Ph), 128.3 (C-4 of Ph), 126.7 (C-
2/C-6 of Ph), 114.8 (seen as a quartet because of coupling to F, 
CF3), 80.9 (CH), 41.5 (CH2NH), 39.9 (CH2CH), 39.1 [C(CH3)3], 
27.9 [C(CH3)3].  
MS (EI): m/z (%) = 407 (4) [M]+, 310 (4), 294 (85), 293 (100), 
278 (3). 
MS (CI): m/z (%) = 425 (60 [M + NH4]+, 408 (5) [MH]+, 329 (11), 
312 (42), 294 (100), 192 (10), 119 (19), 52 (16). 
HRMS-CI: m/z [MH]+ calcd for C22H25F3NO3: 408.1781; found: 
408.1789. 
FT–IR: 3313, 2933, 1635, 1531, 1462, 1227, 1030, 1020, 1000 
cm-1. 
 
(E)-N-(2-(4-Methoxystyryl)benzyl)pivalamide (28) 
0.46 g (97%); Mp 113–115 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.57 (d, J = 8 Hz, 1 H, H-3), 
7.37 (d, J = 9 Hz, 2 H, H-2/H-6 of 4-methoxyphenyl), 7.24 (app. 
dt, J = 2, 8 Hz, 1 H, H-4), 7.18–7.12 (m, 2 H, H-5 and H-6), 7.06 
(d, J = 16 Hz, 1 H, CH=CH), 6.88 (d, J = 16 Hz, 1 H, CH=CH), 
6.80 (d, J = 9 Hz, 2 H, H-3/H-5 of 4-methoxyphenyl), 5.67 (br t, 
exch., 1 H, NH), 4.50 (d, J = 5 Hz, 2 H, CH2), 3.74 (s, 3 H, 
OCH3), 1.05 [s, 9 H, C(CH3)3].  
13C NMR (100 MHz, CDCl3): δ = 178.1 (C=O), 159.9 (C-4 of 
4-methoxyphenyl), 137.4 (C-1), 135.6 (C-2), 130.9 (C-5), 130.4 
(C-1 of 4-methoxyphenyl), 130.2 (C-6), 128.7 (C-4), 128.4 (C-
2/C-6 of 4-methoxyphenyl), 127.7 (C-3), 126.2 (CH=CH), 123.5 
(CH=CH), 114.5 (C-3/C-5 of 4-methoxyphenyl), 55.7 (OCH3), 
42.7 (CH2), 39.1 [C(CH3)3], 27.9 [C(CH3)3].  
EI–MS: m/z (%) = 323 (10) [M]+, 222 (88), 207 (21), 191 (22), 
165 (15), 115 (13), 57 (100). 
CI–MS: m/z (%) = 341 (12) [M + NH4]+, 324 (100) [MH]+, 222 
(7), 119 (18), 52 (17). 
HRMS-CI: m/z [M + NH4]+ calcd for C21H29N2O2: 341.2224; 
found: 341.2225. 
FT–IR: 2961, 1628, 1512, 1453, 1225, 1037 cm-1. 
Anal. Calcd for C21H25NO2: C, 77.98; H, 7.79; N, 4.33. Found: C, 
77.89; H, 7.81; N, 4.30. 
 
(E)-N-(2-(2-Phenylprop-1-enyl)benzyl)pivalamide (29) 
0.34 g (72%); Mp 85–86 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.46 (d, J = 8 Hz, 1 H, H-3), 
7.31-7.18 (m, 8 H, H-4, H-5, H-6 and Ph), 6.79 (s, 1 H, CH), 5.76 
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(br t, exch., 1 H, NH), 4.38 (d, J = 6 Hz, 2 H, CH2), 2.05 (s, 3 H, 
CH3C=CH), 1.06 [s, 9 H, C(CH3)3]. 
13C NMR (100 MHz, CDCl3): δ = 178.4 (C=O), 143.2 (C-1), 
139.0 (C-2), 137.7 (C-1 of Ph), 136.9 (CH=C-CH3), 130.5 (C-5), 
129.0 (C-6), 128.8 (C-3/C-5 of Ph), 128.5 (C-4), 128.3 (C-3), 
128.2 (C-4 of Ph), 127.4 (C-2/C-6 of Ph), 126.3 (CH=C-CH3), 
42.5 (CH2), 39.1 [C(CH3)3], 28.0 [C(CH3)3], 17.6 (CH=C-CH3). 
EI–MS: m/z (%) = 307 (7) [M]+, 222 (4), 206 (38), 191 (18), 178 
(8), 165 (6), 128 (15), 115 (8), 91 (22), 77 (8), 57 (100), 41 (58). 
CI–MS: m/z (%) = 325 (23) [M + NH4]+, 308 (100) [MH]+, 206 
(6), 119 (32), 102 (22), 52 (60). 
HRMS-CI: m/z [MH]+ calcd for C21H26NO: 308.2009; found: 
308.2006. 
FT–IR: 3329, 2921, 1638, 1539, 1357, 1210 cm-1. 
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